Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
about
Surgery for Non-Hodgkin's LymphomaHow I treat HIV-associated lymphomaBurkitt lymphoma in adolescents and young adults: management challenges.Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases.A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.Burkitt's lymphoma masquerading as appendicitis--two case reports and review of the literatureRituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome.Primary cardiac burkitt lymphoma presenting with abdominal pain.Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trialClinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis.Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy.High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers.Low-intensity therapy in adults with Burkitt's lymphoma.Primary Burkitt lymphoma of the supraglottic larynx: a case report and review of the literature.Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.The role of hematopoietic SCT in adult Burkitt lymphoma.Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.Therapeutic approaches to haematological malignancies in adolescents and young adults.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.Treating Burkitt Lymphoma in Adults.Diagnosis and treatment of CD20 negative B cell lymphomas.Oculomotor nerve palsy as a preceding symptom of adult sporadic Burkitt lymphoma: A case report and review of the literaturePopulation-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database.Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013.Jejunal Perforation: A Rare Presentation of Burkitt's Lymphoma-Successful Management.Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma.Early relapse of Burkitt lymphoma heralded by a bone marrow necrosis and numb chin syndrome successfully treated with allogeneic stem cell transplantation.Head and Neck Lymphomas in HIV Patients: a Clinical Perspective.Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma.Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
P2860
Q26771421-C443C885-5734-4072-B3B6-07D5241F5FEFQ26821860-9A3289E8-B7DF-42D4-B322-9AD3E60863CAQ30238965-8F0FDDAC-9BD3-4544-BCF7-3A413A33FF42Q30540646-75561B7D-4EA7-4212-BA85-703E7E2498B6Q33411059-C55D1544-C3A3-4424-9019-5D68656BD7D8Q33441858-E49FF5BD-CD59-45E8-8BC3-B6157FD2894FQ33673144-73A62C98-2521-40C3-A5FF-0845B23311B2Q33823095-6EC8B88D-DCF7-4EE1-9D60-1D750BC8DF00Q34344942-C6176B4B-C015-46A0-9F15-3825EDF2F444Q34347222-CCAB897E-BA5D-494E-90A2-F3A1CF64CC8BQ34560650-FCD293BD-1E79-43F6-B85E-44D071233DB7Q34737471-864E707E-03AD-413A-8B76-95FAC43AA32CQ35021459-F2DFF00E-4DB4-413E-9E80-E9B5EDFD8F2FQ35429833-D66157AB-B90D-4796-895F-0781D30908A1Q35794300-9B9C0DF0-F5AD-43C4-B2AC-EB0F1777192CQ36557585-2CE11264-6E65-4687-A458-569DF782454CQ36620507-E6272C51-7581-4398-81A2-495DFDBD8201Q37273182-935FAC5A-B531-4D53-9B9A-8E5AFB92BCBBQ37476684-3094C562-9CE7-4DFC-8FC6-80BB688CBB29Q37511989-3FB21BF1-D737-4039-81CE-2CF6664C4568Q37692622-35167C4B-3A15-475F-99D8-724FB865E4F8Q37718297-04533D14-E537-43D2-B795-053C922FDE2BQ38031733-272F6EAE-6740-45B0-8839-9262FE3E9C1CQ38096425-8F14EBAE-BCB8-45AD-952B-6A05A54C46EDQ38134399-AB85FC46-E316-4B0E-AA54-0AC96EBEF5ACQ38394272-59C878D3-4D96-45EE-897F-F211F693F11DQ38465823-7604EA58-C0D7-49CA-B811-B614989E616FQ38503297-FB858285-8FDD-4F85-AAAD-F4C827B5302EQ39132786-3F85F1F3-2BE3-47C4-88F9-34E2E573C0FBQ39270336-D02AEEFB-A0FA-49B2-BBB1-1EA85174ACC2Q39372883-F57B62E0-7956-43AA-BFB2-996007A12BB3Q40071847-2EC75A0E-EE71-471E-8A6C-F967B401FE37Q40411469-11FDD686-9165-4089-9AB4-AE11BFC1343FQ40960748-1004B35D-C7C6-4F8F-80EA-6909D3184213Q41663533-0DFE5BA0-43B2-41AA-90D0-8B731E10F01BQ41761179-4FF87E67-4105-4677-A1C6-3BFF034B3015Q41919568-F93CDDA9-3B5D-47F2-AFEA-45B1B0734883Q42277126-1BF3BA20-2E4C-4371-9DC3-094625C4E369Q43752446-124C559A-E1B7-4967-B3F0-AFD9AD8EE14BQ47361098-DDC7446C-0884-49C3-821C-D2C82235D0B4
P2860
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evaluation of the addition of ...... oma: a retrospective analysis.
@ast
Evaluation of the addition of ...... oma: a retrospective analysis.
@en
Evaluation of the addition of ...... oma: a retrospective analysis.
@nl
type
label
Evaluation of the addition of ...... oma: a retrospective analysis.
@ast
Evaluation of the addition of ...... oma: a retrospective analysis.
@en
Evaluation of the addition of ...... oma: a retrospective analysis.
@nl
prefLabel
Evaluation of the addition of ...... oma: a retrospective analysis.
@ast
Evaluation of the addition of ...... oma: a retrospective analysis.
@en
Evaluation of the addition of ...... oma: a retrospective analysis.
@nl
P2093
P2860
P356
P1433
P1476
Evaluation of the addition of ...... oma: a retrospective analysis.
@en
P2093
A S Lacasce
C E Toomey
E P Hochberg
J A Barnes
J S Abramson
J S Michaelson
P2860
P304
P356
10.1093/ANNONC/MDQ677
P577
2011-02-21T00:00:00Z